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Summary for the brain (Stanley 1987; Coates and Tanaka 1992),
The overall fatty-acid oxidation in mitochondria re- 
The carnitine-acylcarnitine carrier (CAC) catalyzes the quires the conceited action of at least 17 different pro­
translocation of long-chain fatty acids across the inner 
mitochondrial membrane. We cloned and sequenced the 
human CAC cDNA, which has an open reading frame 
of 903 nucleotides. Northern blot studies revealed dif­
ferent expression levels of CAC in various human tissues. 
Furthermore, mutation analysis was performed for a 
CAC-deficient infant. Direct sequencing of 
the patient’s cDNA revealed a homozygous cytosine nu-
teins, including 16 enzymes and the transporter CAC. 
Genetic defects have been identified in most of these 
proteins (Stanley 1987; Stanley et ah 1992), These de­
fects generally present in early infancy, with acute, po­
tentially life-threatening episodes of hypoketotic hypo­
glycemic coma induced by fasting. The clinical 
phenotypes are very similar and can be attributed to one 
of three major types of presentation, with predominantly
cleotide insertion. This insertion provokes a frameshift hepatic, cardiac, or skeletal muscle involvement (Kelly
and an extension of the open reading frame with 23 and Strauss '1994; Pande and Murthy 1994; Pollit 1995).
novel codons. This is the first report documenting a mu- So far, six cases of CAC deficiency have been reported
tation, in the CAC cDNA, responsible for mitochondrial (Stanley et al. 1992; Pande et al. 1993; Brivet et al. 1994,
/3-oxidation impairment
Introduction
The carnitine-acylcarnitine carrier (CAC) shuttles acyl- 
carnitine esters, in exchange for free carnitine, across the 
inner mitochondrial membrane (Pande 1975; Ramsay 
and Tubbs 1975). This transport is an essential step in 
the process of long-chain fatty-acid oxidation (Stanley
1987; Coates and Tanaka 1992; Stanley et al. 1992).
1996; Niezen-Koning et al. 1995; Ogier de Baulney et 
al. 1995). The main features in these severely affected 
patients with onset in the neonatal period are hypoke­
totic hypoglycemia, mild hyperammonemia, variable di- 
carboxylic aciduria, hepatomegaly with abnormal liver 
functions, various cardiac symptoms, and skeletal mus­
cle weakness. In all cases, CAC activity in cultured skin 
fibroblasts is below detectable levels. However, so far, 
the CAC deficiency has not been characterized at the 
molecular level, in any patient.
Fundamental properties of eukaryotic CAC] have been 
investigated extensively in intact mitochondria (Pande
The oxidation of fatty acids in mitochondria plays an 9 ^ ;  Ramsay and Tiihbsl 975 ;Pande a j t a n  1980;
important role in energy production. During fasting, [^ H;Wonger 1981; Murthy and Pande 1984) and after
fatty acids are used for hepatic ketone-body synthesis. purification and reconstitution into liposomes (Indiver.
Furthermore, fatty acids are an important source of en- ct 1990, 1991(7, 19Jib,  19 2, 19M, li-. 5). Ih eca i-
ergy for heart muscle and also for skeletal muscle, during 
exercise, whereas ketone bodies are excellent substrates
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rier is embedded in the inner mitochondrial membrane 
and has an apparent molecular mass of 32.5 kD in rat 
liver (Indiveri et al. 1990). It governs a one-to-one 
exchange, between long-chain acylcarnitine esters and 
nonesterified carnitine, across the inner mitochondrial 
membrane and also the unidirectional transport of car­
nitine across this membrane, although less efficiently 
(Pande and Parvin 1980; Indiveri et al. 1991a). Incor­
porated into liposomes, the purified carrier protein has 
substrate specificity and inhibitor sensitivities similar to
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those in intact mitochondria (Indiveri et al. 1990,1991#, 
1991£>). CAC operates according to a ping-pong mech­
anism (Indiveri et al. 1994).
Very recently we described the cDNA and amino acid 
sequence of the rat CAC (Indiveri et al. 1997). These 
studies have shown that CAC belongs to a protein family 
that, so far, has been found to comprise 10 biochemically 
well-characterized mitochondrial carriers and also sev­
eral other members of unknown function that are be­
ginning to emerge with the advance of genomic DNA  
sequencing (Walker and Runswick 1993; Palmieri 1994; 
Crabeel et ah 1996; Palmieri et al. 1996). These proteins 
have evolved from a common ancestor, by two-tandem 
gene duplication, and have related structures and mech­
anisms (Walker and Runswick 1993; Palmieri 1994).
We report on the nucleotide sequence of the human 
CAC cDNA and the corresponding amino acid sequence, 
as well as the distribution of CAC mRNA in human 
tissues. For the first time, a mutation has been found in 
the CAC cDNA of a unique, now 9-year-old, CAC-de- 
ficient patient.
Patient and Methods
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Case Report
This 9-year-old girl with a normal family history sur­
vived a severe neonatal condition consisting of hypo­
glycemia, cardiac arrest, hepatomegaly, and hepatic dys­
function. These features are often observed in patients 
with a fatty-acid oxidation disorder. Thereafter episodes 
of lethargy and hepatomegaly occurred only during mild 
viral infections. Acylglycines were nondiagnostic, and 
acylcarnitines showed increased medium- to long-chain 
hydroxy and unsaturated derivatives. A liver biopsy
showed fatty infiltration. During the last few years, she (sense H7? 5 -CCTGGTGTTTGTGGGGCACCCCTTG- 
has had a rather normal physical and neur©physiological  ^ 455-480 (antisense 1R, 5 -CTGAATCTGCAG- 
development: she has done well with prolonged exercise, TAAGCATTTGATC-3); 405-430 (sense 2F, 5-GGG- 
and in between the attacks she is an alert, cooperative, ATGTTATCTGGTGTGTTCACCA-3 ); and 937-962
and pleasant young girl. Her symptoms are much milder 
than those in the other CAC-deficient patients who have 
been described. Cultured skin fibroblasts were sent to
Figure 1 Nucleotide sequence of  human CAC cDNA. The de­
duced amino acid sequence of  the open reading frame of 903 bp (301 
codons) is shown below the nucleotide sequence. H u m a n  CAC amino 
acids that  differ from those of  rat CAC (Indiveri et al. 1997) are shown 
in underlined, italicized print. The cDNA and deduced protein 
sequences are in GenBank (accession no. Y 10319; http:// 
www.ncbi.nhm,nih.gov/Web/Genhank/index.htm),
(antisense 2R, 5'-ACAAGTTGGGGGCAATCCAATT
GAG-3'). These primers (Pharmacia Biotech) were used 
in PCRs, to amplify cDNA fragments encoding the hu-
one of us (R.W.) to investigate a possible defect in mi- man ^vej The template was first-strand cDNA
reverse transcribed, with oligo(dT) by AMV reverse
transcriptase (Boehringer Mannheim) for 1 h at 55°C, 
from human liver mRNA (Clontech). PCR reactions 
were carried out for 30 cycles (94°C for 30 s, 60°C for 
1 min, and 72°C for 2 min). At the end, a single incu­
bation at 72°C for 7 min was added. The extension to 
the y  end was performed by priming from poly(A), with 
two nested forward primers (AGAAGAAGGAGTCA- 
CCTCCTTGTA and C A A AGGGTT C A ATGC AGT CA- 
TGA, corresponding to nucleotides 831-854 and 
Oligonucleotides were designed on the basis of the 855-877, respectively, of the rat cDNA sequence). To 
cDNA sequence of the rat liver CAC (Indiveri et al. extend the sequence to the 5' end, a touchdown PCR 
1997), at the following nucleotide positions: 125-150 (Don et al. 1991) was performed on an adaptor-ligated
tochondrial fatty-acid oxidation.
Fibroblast Study
Overall /3-oxidation in fibroblasts was measured as 
described previously by Olpin et al. (1992). The CAC 
activity in fibroblasts was measured essentially according 
to the study by Pande et al. (1993).
Cloning and Sequencing o f the Human CAC
Huizing et al.: Cloning of Human CAC and Mutation Detection 1241
A
H B P Lu L SM K Pa
2.40
1.35
-.V. ¿U/:-
B
2.40
1.35
Figure 2 Expression of CAC m R N A  in human tissues. Nor thern  
blots (2 /¿g poly| A] RNA/tissue) hybridized with a hum an CAC probe  
(/\) and an actin probe (B) are shown.  The molecular weight is indi­
cated in the figure: hum an C A C  m R N A  is ~I.K kb. Results for the 
following tissues are shown: hear t  (H), brain (B), placental (P), lung 
(Lu), liver (L), skeletal muscle (SM), kidney (K), and pancreatic (Pa).
21-41 and 481-501, respectively, of the human CAC 
cDNA sequence (fig. 1); for fragment 2, 5;-CCTGGA-
GAACGGATCAAGTG-3' (sense F2) and 5-CAATTA- 
AGGAACTTCATGGCAA-3' (antisense R2), at posi­
tions 450-469 and ,928-949, respectively; and, 
for fragment 3, 5/-GCAGTGATGATCCGAGCCTTC-3/ 
(sense F3) and 5'-ACAGGTAGTATCTGGTCTGGAA- 
3' (antisense R3), at positions 873-893 and 1224-1245, 
respectively. For each fragment, 35 cycles of PCR were 
performed (92°C for 60 s, 60°C for 60 s, and 72°C for 
90 s). The cycles were preceded by an initial denatura­
tion step at 95°C for 3 min and were followed by a final 
extension at 72°C for 10 min. Ten microliters of each 
PCR reaction was analyzed on 1.0% agarose gels with 
0,5 /xg ethidium bromide/ml in 1 x Tris borate-EDTA. 
The nucleotide sequences of the PCR products were an­
alyzed by direct sequencing using the Tacj Dye Deoxy 
Terminator Cycle Sequencing Kit (Applied Biosystems), 
according to the manufacturer's recommendations,
Results
double-stranded human liver cDNA (Clontech). In
this case we employed two nested forward adaptor prim- Cloning and Sequencing o f Human CAC cDNA
ers and two reverse-specific primers (TTGTGTCTG-
CAGTCGGACCTTGAC and CCAGAGGGTGACCG-
Tlie recently reported rat cDNA of CAC (Indiveri et 
al. 1997) was used for cloning and sequencing of the
ACGAACACCAGGC, corresponding to nucleotides human CAC homologue. Four overlapping sequences
257-278 and 121-146, respectively, of the rat cDNA were amplified, by PCR using human liver cDNA as a
sequence), DNA-sequence analysis was performed ac~ template, with synthetic oligonucleotide primers based
cording to established procedures (Indiveri et al. 1997), on the m t CDNA sequence and, to extend the sequence
to the 5' end, with two nested forward primers comple-
Noi them Biol Analysis nientary to adaptors that were added to the 5' extremities
The sequence corresponding to nucleotides 421-967 ° f  the human liver cDNA. The obtained cDNA sequence
of the human CAC cDNA was used as a probe in north- was 1,243 bp in length and had an open reading frame
ern blots performed on mRNA derived from various 
human tissues (Clontech). Northern blot analysis was 
performed according to standard protocols, with high 
stringency. The filters were autoradiographed at -80°C.
of 903 bp (fig, 1). Assignment of position 63 as the first 
nucleotide of the initiation codon was deduced from 
comparison with the CAC cDNA of rat liver (Indiveri 
et al. 1997), since no stop codon was found in the 5'
For normalization of the hybridization signals a probe UTR. I he sequence, which extended into the 3' non- 
encoding part of human actin (Clontech) was employed. coding region, did not contain the polyadenylation sig­
nal. The protein encoded by the human CAC cDNA 
contains 30 1 amino acids, and its calculated molecular 
weight is 32,9 Id).
Mutation Detection
Total RNA was extracted (Chomczynski and Sacelli 
1987) from cultured skin fibroblasts and was stored as »
an ethanol precipitato at -  80“C. A 5-Mg sample of RNA (>l LAC >"RNA Human
was reverse transcribed to cDNA, in 1 h at 42C>C, with A hybridization probe consisting of nucleotides 
421-967 of the human liver CAC" cDNA was employed 
in northern blot experiments. Figure 2 shows the pres­
ence of one band for CAC mRNA, -1 .8  kb in length,
200 U of Superscript II reverse transcriptase (Life Tech­
nologies), by use of oligo(dT) and random hexamer 
primers. Five microliters of this first-strand cDNA was 
subjected to PCR amplification. By PCR, we generated in various human tissue types. The CAC mRNA was 
three overlapping fragments that covered the entire cod- highly expressed in heart, skeletal muscle, and liver ris­
ing region, using the following synthetic oligonucleotide sues. A much lower level of expression was found in 
primers (Perkin Elmer): for fragment 1, 5'-GCAGGT- brain, placental, pancreatic, and kidney tissues and es- 
CGAGAACTGACAGAC-3' (sense FI) and 5'~TTTCTC~ pecially in lung tissue. These differences in the level of 
CTGAAGAAGCCTGAA-3' (antisense Rl), at positions expression of the CAC transcript in the various tissues
1242 Am. ]. Hum. Genet. 61:12.V)-124.S, 1997
Table 1
Overall 0-Oxidation Rates and CAC Activities in Cultured 
Skin Fibroblasts of the Patient and of Controls
Pat ien t Controls {n)A
Overall /3-oxidation (nmol/h/mg):
[9 , lO- 'HJMynst ic  acid 4.1 6.0 ±  2.3 (61)
[9, IQ-1!-!] Pal mi tic acid 2 .4 8,8  ±  4.1 (33)
CAC activity (pmol/min/mg):
Produced HC 0 2 N D È' 4 7  ±  16 (5)
“ D a ta  are the mean ±  SD. // =  no. o f  controls. 
h N D  -  n o t  detectable,
tested were not due to variations in the amounts of RNA
32.9 kD. The amino acid sequences of human and rat 
CAC are highly conserved: there is ~90% identity be­
tween these species (fig. 1) (Indiveri et al. 1997). Human 
CAC differs from its rat counterpart in 29 amino acids, 
15 of which are nonconserved. The identity between the 
human and rat CAC is less than that found for some 
other mitochondrial carriers. In fact, 97% identity was 
found between the human and rat 2-oxoglutarate car­
riers (lacobazzi et al. '1992; Dolce et al. 1994/;), and 
95% identity was found between the human and rat 
citrate carriers (Kaplan et al. 1993; lacobazzi et al. 1997) 
and phosphate carriers (Ferreira et al, ‘1989; Dolce et al. 
1994a). Three repeated homologous domains, each 
100 amino acids in length, can be distinguished in the
loaded on the gel, since this was checked in a control human CAQ a characteristic previously recognized in
experiment with an actin probe. 
Biochemical Studies in the Index Patient
other mitochondrial transport proteins (Walker and 
Runswick 1993; Palmieri 1994). These domains are re­
lated to those found in the mitochondrial carrier-protein
Biochemical measurements of intact cultured skin fi- family (Walker and Runswick 1993; Palmieri 1994).
broblasts showed a diminished oxidation rate of The cDNA and deduced protein sequences are in
labeled myristic and palmitic acid (66% and 27%, re- GenBank (accession no. Y10319; http://www.ncbi.nhm 
spectively, of the control mean), as shown in table 1. .nih.gov/Web/Genbank/index.htni). A Blast search for 
The oxidation rate of MC-labeled octanoate and butyrate 
was found to be normal (not shown). The activities of 
the various mitochondrial fatty acyl-CoA dehydrogen­
ases, the enoyl-CoA hydratases, the 3-hydroxyacyl-CoA 
dehydrogenases, and the 3-ketoacyl-CoA thiolases, as 
well as of carnitine palmitoyltransferases I and II, were 
all normal (not shown). As shown in table 1, the activity 
of CAC was not detectable.
Ala Thr Pro Asn Leu Stop - - 
G C C A C C C C C A A C T T G T G A G G
Mutation Analysis
The CAC mRNA from cultured skin fibroblasts from 
the patient was reverse transcribed, and the cDNA was 
PCR amplified in three overlapping fragments. Sequenc­
ing of these fragments revealed an insertion of a cytosine 
in the cytosine-rich region of bp 955-959, as shown in 
figure 3. This insertion changes the sequence of the CAC 
protein from amino acid 300 (asparagine to glutamine) 
to the carboxy terminus and expands the length of the 
protein by 2*1 amino acids, to 322 amino acids (fig. 4A)<
Hydrophilicity calculations were performed according 
to the Kyte-Doolittle method, for the peptide sequence 
of the wild-type and the patient’s CAC. The values ob ­
tained were used for Chou-Fasman predictions of the 
secondary structure of the protein. The Chou-Fasman 
two-dimensional plot (fig. 4J3) showed a dramatic con­
formational change, at the C-terminal region, between 
the wild-type and the patient’s CAC protein.
Discussion
I
B Ala Thr Pro Q\n Ufiu Yai Am
G C C A C C C C C C A A C T T G T  G A G G
Primary Structure o f Human CAC
The protein encoded by the hum an CAC gene is 301 
amino acids long, and its calculated molecular weight is
F i g u r e  3  Sequences of CAC cD N A  segments,  with their accom ­
panying amino acid codes, for a control  (wild type) (/V) and  the patient 
(i3). For the patient,  a C insertion, resulting in a frameshift and an 
extension of the C terminus o f  the CAC] protein (underlined), is shown 
(arrow).
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Figure 4 /\, Primary C-terminnl amino acid sequence of wild-type (top) and  p a t ie n t ’s (bottom )  C A C  protein ,  ft, Predicted secondary 
structure, according to the Chou-Fasm an  algorithm, of wild-type (tof)) and  pa t ien t ’s e longated (bottom )  CAC,
rous se seven •rerent ex heart, skeletal muscle, and liver tissues, which is in fair
pressed-sequence-tag (EST) clones (AA305590, R l 1780, agreement' with the clinical involvement of these tissues
F08483, Z28872, AA378439, N77642, and N87428) in the patient. Much lower levels of expression were
that originated from different human tissues. These EST found in brain, placental, kidney, and pancreatic tissues
clones have sequences that are homologous with differ- and especially in lung tissue, 
ent parts of the CAC protein and are presumed to encode 
a carrier protein of unknown function.
Tissue Distribution o f  CAC mRNA
CAC-D efident Patient
We have identified CAC deficiency in cultured skin 
fibroblasts from a child who survived a stormy neonatal 
The CAC defect was detected in the patient’s fihro- period due to her fatty-acid oxidation disorder, which 
blasts. It is likely that CAC deficiency occurs in all tis- invariably has been fatal in other patients (Stanley et al. 
sues, since no evidence for the existence of various tissue- 1992; Pande et al. 1993; Brivet et aL 1994, 1996; Hi- 
specific isoforms has been found. As shown in figure 2, ezen-Koning et al, 1995; Ogier de Baulney et al. 1995), 
high levels of CAC mRNA transcripts were found in Direct sequencing of the entire cDNA of the patient re-
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vealed the presence of a homozygous insertion of a cy­
tosine nucleotide in the only cytosine-containing region, 
bp 955-959, resulting in a frameshift. We repeated se­
quencing of the cDNA of this patient and of three con­
trols, in three independent experiments, all of which re­
vealed the homozygous insertion in the patient’s cDNA. 
This excludes the possibility of a mistake made by the 
Taq DNA polymerase in the PCR reaction. The region 
containing the insertion consists of five cytosine nucle­
otides, which makes confirmation of the insertion by 
restriction-enzyme analysis impossible. Unfortunately, 
no material from the other family members was available 
for further investigations,
The CAG protein of the patient has an obviously 
changed C terminus: amino acids 300 and 301 are 
changed from asparagine and leucine, respectively, to 
glutamine and leucine, respectively, and the protein has 
been elongated by 21 amino acids. A Chou-Fasman pre­
diction shows a dramatically changed secondary struc­
ture. The C terminus is changed from a turn (in wild- 
type CAC) to a helix structure, in the patient. The 
molecular basis of the transport process mediated by the 
CAC is still unrevealed. A proper folding and orientation 
of the CAC protein in the mitochondrial membrane is 
crucial for adequate functioning. The novel extension in 
the patient contains a hydrophobic domain, which may 
be embedded in the mitochondrial inner membrane in­
stead of protruding into the intermembrane space. A 
diminished entrapping or binding capacity of the posi­
tive charge of the quaternary nitrogen of carnitine to the 
negative carboxylate of the CAC C-terminus can be hy­
pothesized for die patient. The alterations of the pa­
tient’s CAC also may lead to instability of the protein. 
An impairment of the patient’s CAC in substrate binding 
or translocation also can be considered. The functional 
consequences of the molecular defect apparently are re­
stricted, in view of the mild clinical phenotype of the 
patient. Surprisingly, no CAC activity was detectable in 
fibroblasts.
In the present study, we determined the sequence of 
the human cDNA of the mitochondrial CAC, showed 
differences in human tissue distribution, and defined the 
first molecular defect in a CAC-deficient patient. This 
study provides the techniques necessary to resolve the 
molecular basis of CAC deficiency. This may be of great 
importance for the reliable diagnosis of patients at risk 
and also may guide the way toward prenatal diagnosis 
of this severe type of inborn error in metabolism.
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